Abstract: The present invention relates to compounds of formula (I) AA1-AA2-D-Ile-AA3-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D- Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 (I) or a pharmaceutically acceptable salts thereof, to processes for their obtention and to their therapeutic indications.

Abstract: The subject invention concerns materials and methods for modulating lignin biosynthesis in sugarcane plants. In one embodiment, lignin biosynthesis is down-regulated. Genes and the proteins encoded thereby that can be targeted for achieving down-regulation of lignin in sugarcane include, for example, 4-coumarate-CoA ligase (4CL). In one embodiment, the 4CL gene is 4CL-M, 4CL-N, or 4CL-L. The subject invention also concerns a sugarcane plant, specific plant tissue, and plant cells having modulated (e.g., down-regulated) lignin biosynthesis. The subject invention also concerns methods for producing a sugarcane plant having modulated (e.g., decreased or down-regulated) biosynthesis of lignin.

Abstract: A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitrea or subconjuntival means or under the form for topical administration.

Abstract: The subject invention concerns materials and methods for modulating lignin biosynthesis in sugarcane plants. In one embodiment, lignin biosynthesis is down-regulated. Genes and the proteins encoded thereby that can be targeted for achieving down-regulation of lignin in sugarcane include, for example, 4-coumarate-CoA ligase (4CL). In one embodiment, the 4CL gene is 4CL-M, 4CL-N, or 4CL-L. The subject invention also concerns a sugarcane plant, specific plant tissue, and plant cells having modulated (e.g., down-regulated) lignin biosynthesis. The subject invention also concerns methods for producing a sugarcane plant having modulated (e.g., decreased or down-regulated) biosynthesis of lignin.

Abstract: A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitrea or subconjuntival means or under the form for topical administration.